Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27172955 | 1.00 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2CTSKALDH1A1NR1H2 | |
| SCHEMBL21408159 | 0.80 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL27172965 | 0.78 | POLB (0.32) | L3MBTL1 | |
| SCHEMBL16031037 | 0.77 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL21408127 | 0.77 | ALDH1A1 (0.34) | HSD17B10SMN1; SMN2CTSKALDH1A1NR1H2 | |
| SCHEMBL16031035 | 0.77 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL16031033 | 0.77 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL16148112 | 0.77 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL17922893 | 0.76 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD | |
| SCHEMBL17922894 | 0.76 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2CTSKALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12433897-B2 | Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| CN-119119062-A | Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119063-A | Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240342186-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-10-17 | — | — | US | disclosed |
| EP-4337326-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2024-03-20 | — | — | EP | disclosed |
| CN-117337292-A | Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| WO-2022238327-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342186-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | HSD17B10 1489/4885SMN1; SMN2 2556/4885CTSK 1124/4885 |
| US-20250360141-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | HSD17B10 1669/4885SMN1; SMN2 2437/4885CTSK 1166/4885 |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | HSD17B10 1489/4885SMN1; SMN2 2556/4885CTSK 1124/4885 |
| US-12433897-B2 | Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors | CGAS, GLS2, GMPS | HSD17B10 1489/4885SMN1; SMN2 2556/4885CTSK 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.